Drug allergy
Causes and desensitization

Richard Warrington
Section of Allergy & Clinical Immunology; Departments of Internal Medicine & Immunology; University of Manitoba; Winnipeg, MB Canada

**Keywords:** drug allergy, drug allergy pathogenesis, desensitization

Allergic drug reactions occur when a drug, usually a low molecular weight molecule, has the ability to stimulate an immune response. This can be done in one of two ways. The first is by binding covalently to a self-protein, to produce a haptenated molecule that can be processed and presented to the adaptive immune system to induce an immune response. Sometimes the drug itself cannot do this but a reactive breakdown product of the drug is able to bind covalently to the requisite self-protein or peptide. The second way in which drugs can stimulate an immune response is by binding non-covalently to antigen presenting or antigen recognition molecules such as the major histocompatibility complex (MHC) or the T cell receptor. This is known as the p-I or pharmacological interaction hypothesis. The drug binding in this situation is reversible and stimulation of the response may occur on first exposure, not requiring previous sensitization. There is probably a dependence on the presence of certain MHC alleles and T cell receptor structures for this type of reaction to occur.

There is increasing evidence for the need for specific MHC alleles to be present in order for drug reactions to occur. This requirement varies between ethnic groups and may be limited to certain drugs and certain forms of hypersensitivity reactions, such as Stevens-Johnson/Toxic epidermal necrolysis. It has also become more evident that there is an interaction between drug hypersensitivity reactions and viral infections, best known with the maculopapular rashes occurring with amino-penicillins but clearly demonstrated in the drug-induced Hypersensitivity Syndrome, where an interplay of drug-induced immune responses and Herpes viruses occurs. There is increasing evidence for the ability of drugs to initiate immune responses through activation of the innate immune system. In addition, drug reactions can appear to involve the adaptive immune system when in fact the manifestations are due to direct effects upon mediator-containing cells such as mast cells, or other inflammatory systems such as prostanoids and the kinin system.

In the presence of drug hypersensitivity, it is sometimes necessary to re-institute administration of the implicated drug because no satisfactory alternatives are available. There have been significant advances in such techniques, particularly for reactions considered to be immediate or anaphylactic in type, and there is increased understanding of the mechanisms that may be involved in desensitization. However many drug reactions appear to involve cell-mediated immune responses, and while desensitization in milder forms of drug hypersensitivity is performed, little is known of the mechanisms involved.

Adverse drug reactions are frequently classified into two types. Type A reactions are common and are caused by the pharmacologic or toxic effects of the drug. Type B reactions are uncommon and unpredictable, occurring in susceptible and predisposed individuals. These include allergic drug reactions, making up about 15% of all adverse drug reactions.1

**Pathogenesis of Immune Response to Drugs**

Because most drugs are low molecular weight chemicals, in theory too small to be able to stimulate the immune system, it has long been assumed that the drug or a reactive metabolite, must first bind covalently to a macromolecule such as a protein, forming a multivalent conjugate that is processed and presented by the immune system to T lymphocytes.3 This mechanism would not be required for large molecular weight drugs that express multiple epitopes. These would include proteins or peptides used therapeutically such as monoclonal antibodies, and cytokines such as interferons and growth factors, as well as succinylcholine and other neuromuscular drugs that express quaternary ammonium epitopes that can cause such drugs to become multivalent.3

Probably the clearest example of drug haptenation is that which occurs with penicillin which is chemically reactive and

---

**Abbreviations:**
- ACE, angiotensin-converting enzyme; AERD, aspirin exacerbated respiratory disease; APC, antigen presenting cell; ASA, acetyl salicylic acid; CFSE, carboxyfluorescein diacetate succinimidyl ester; CTL, cytotoxic T lymphocytes; DAMP, damage-associated molecular pattern; DIHS, drug-induced hypersensitivity syndrome; DILI, drug-induced liver injury; DRESS, drug rash with eosinophilia and systemic symptoms; FasL, fas ligand; FcεRI, high affinity IgE receptor I; HLA, human leukocyte antigen; MHC, major histocompatibility complex; NK, natural killer; NKT, natural killer T cell; NSAID, non-steroidal anti-inflammatory drug; PCR, polymerase chain reaction; PXR, pregnane X receptor; SHIP, SH2-containing inositol phosphatase; SJS, Stevens-Johnson syndrome; TCR, T cell receptor; TEN, toxic epidermal necrolysis; Th, T helper

**Correspondence to:** Richard Warrington; Email: rwarrington@hsc.mb.ca
Submitted: 07/18/12; Revised: 08/13/12; Accepted: 08/20/12
http://dx.doi.org/10.4161/hv.21889

www.landesbioscience.com
undertakes stable covalent binding to proteins or peptides, resulting in the creation of an immunogenic self-protein. There is evidence that this often happens with albumin, perhaps because it is a common serum and tissue protein. The extent of haptenation that occurs may be dependent on the concentration of drug available but also depends on other factors, since fewer than 20% of available lysine molecules on albumin are modified by β-lactams. In the case of penicillins, we have considerable information on the penicillin derivatives that are responsible for sensitization and the production of the acute reaction. Penicillins bind to amino acids because the β-lactam ring opens spontaneously and forms stable covalently bound conjugates with proteins. This results in a penicilloyl epitope which is immunodominant in penicillin-specific immune responses. Haptenation can also occur through carboxyl and thiol groups to form minor determinants.

The related cephalosporins also can form hapten-protein conjugates, but this is slower and less efficient. It is presumed that a cephalosporyl determinant is generated between the β-lactam ring and lysine residues but the conjugate is unstable and fragments in the dihydrothiazine ring. These multiple breakdown products are not well defined, but it appears that IgE antibodies can bind to the side chains, to the β-lactam ring or the whole molecule.

Sulfamethoxazole is a drug which does not react covalently with proteins but becomes reactive through cytochrome P450 metabolism, first to sulfamethoxazole hydroxylamine and then by auto-oxidation to a nitroso intermediate which modifies thiol group on proteins. SMX-NO binds to non-MHC-associated protein, generating a protein conjugate that stimulates T-cell receptors via a hapten mechanism involving processing of the conjugate and liberation of antigenic peptide fragments (Fig. 1). N-acetyl transferase polymorphisms may play a role in determining this hypersensitivity response. But sulfamethoxazole can also interact directly with antigen-presenting cell receptors.

### Processing Drug-Conjugates

The drug or a reactive product reacts with a self-protein or peptide which results in formation of a novel drug-conjugate or adduct. This undergoes antigen-processing to generate a small but novel MHC ligand that is loaded onto the MHC and transported to the cell surface, where it can interact with antigen-specific T cells (Fig. 1). This process requires a metabolically active antigen-presenting cell and time. Once generated, the MHC-drug-peptide complex is stable and ligand removal requires peptide exchange or peptide stripping from the MHC groove.

### The P-I Concept

However, not all drugs seem to be capable of interacting covalently with proteins, and some immune reactions to drugs occur without antigen-processing. This has led to the pharmacological interaction or p-i hypothesis, whereby some chemically inert drugs are able to bind non-covalently to antigen-presenting structures such as the T cell receptor or MHC and cause stimulation directly of an immune response, as is the case with sulfamethoxazole. Most drugs have been designed to fit into protein pockets in receptors and enzymes. This is the pharmacophore concept, based upon steric and electronic features that permit optimal interaction with a specific biologic target to trigger or block the target’s biologic response. The p-i hypothesis has been derived from experimental work with T cell clones and TCR-transfected hybridomas expressing drug-specific receptors. The drug interaction with the receptor is highly specific such that small changes in drug structure can affect reactivity. T cell activation can occur rapidly, before metabolism and processing of the drug could occur. However the reactions that occur are the same as those induced by a drug-modified peptide antigen, since the immune response once activated proceeds in a fixed way. The hypothesis could explain why reactions can sometimes occur without known previous sensitization.

Evidence in favor of the p-i hypothesis is (1) aldehyde fixed antigen presenting cells (APC) are able to activate drug-specific T cell clones if incubated with the drug, (2) drug binding by this mechanism is labile and reversible, (3) calcium influx into T cell clones exposed to the drug occurs within seconds, (4) elution of peptides from HLA-B*1502, which presents carbamazepine to drug-reactive T cell clones, does not show the presence of covalently bound carbamazepine modified peptides.

In the case of sulfamethoxazole, interaction with the TCR occurs in the CDR2 and CDR3 regions of TCR Va and Vb, where there are presumably drug binding sites. But in addition, it has been proposed that drugs might bind to certain HLA-B alleles and the modified allele is then recognized by the TCR. Finally binding may first be to the TCR giving a partial activation followed by the TCR interacting with drug bound to HMC class II molecules, resulting in complete activation of the T cells (Fig. 2).

T cells from sulfamethoxazole-allergic patients can be stimulated with the parent drug sulfamethoxazole and SMX-NO bound directly to MHC molecules and specific T-cell receptors. Both the parent drug and drug metabolite apparently contain the steric and electronic features required to ensure molecular interactions with both immunologic receptors and stimulation of a T-cell.
TCR activation but high affinity binding to the receptor is necessary. So drug binding may convert a low affinity antigen to a high affinity antigen.

While drugs have the potential to provide maturation signals to dendritic cells, acting as co-stimulatory agents, at the time when drugs are being administered, these cells may also receive maturation signals from other sources such as infections or other diseases or trauma. Lavergne et al. demonstrated metabolism maturation signals from other sources such as infections or other diseases or trauma. Sulphamethoxazole and its metabolites as well as abacavir have been shown to induce CD40 expression on dendritic cells. This response was blocked by inhibition of metabolism in the zole stimulated drug-reactive cells cloned from allergic individuals. Three major types of reactions have been considered responsible for these reactions, 1) Fas-FasL (Fas Ligand) interactions, 2) the perforin/granzyme B pathway, 3) granulysin. Viard et al. proposed that Fas-FasL interactions were responsible for apoptosis of keratinocytes in SJS/TEN. However this hypothesis has been questioned and a role for perforin/granzyme B suggested. Activated CTLs and NK cells produce perforin and this can open a channel in the target cell membrane to allow granzyme B to enter, which activates the caspase cascade. The 15-kDa granulysin is secreted by CTLs and NK cells and is present in blister fluid in SJS/TEN. This has a cytotoxic effect on keratinocytes and also acts as a natural killer (NK) cell-mediated reactions. 31 Three major types of reactions may be involved in the generation of the allergic drug reaction. The association with HLA-B*5701 is strong enough that the US Food and Drug Administration issued an alert in 2008 recommending pre-screening for this allele before prescribing the drug.

In Han Chinese and other Asian populations, Stevens-Johnson/Toxic Epidermal Necrolysis induced by carbamazepine is strongly associated with HLA-B*1502. This association does not exist in Europeans, where an association with HLA-A*3101 has been reported. This does not appear that carbamazepine covalently modifies peptides which are presented in MHC but rather that carbamazepine or it metabolites binds directly to endogenous peptides already present there. However, not all HLA-B*1502 bearing patients react in this way to carbamazepine. This appears to be due to the requirement for a particular structure of the T cell receptor. T cell clones from HLA-B*1502 donors with carbamazepine hypersensitivity express the predominant TCR clonotype VB-11-ISGSY. This was found in 84% of 19 patients with SJS/TEN but was absent in carbamazepine-tolerant patients. It is present in 14% of healthy subjects. If peripheral blood mononuclear cells from normal donors expressing HLA-B*1502 and VB-11-ISGSY were primed with carbamazepine, a cytotoxic T cell response was induced that could be blocked with anti-TCR-VB-11. Thus the appropriate HLA allele and T cell receptor clonotype is required for the carbamazepine immune response to occur in this population.

The severe mucocutaneous lesions of SJS/TEN are usually explained on the basis of cytotoxic T lymphocytes (CTLs) natural killer (NK) cell-mediated reactions. Three major types of reactions have been considered responsible for these reactions, 1) Fas-FasL (Fas Ligand) interactions, 2) the perforin/granzyme B pathway, 3) granulysin. Viard et al. proposed that Fas-FasL interactions were responsible for apoptosis of keratinocytes in SJS/TEN. However this hypothesis has been questioned and a role for perforin/granzyme B suggested. Activated CTLs and NK cells produce perforin and this can open a channel in the target cell membrane to allow granzyme B to enter, which activates the caspase cascade. The 15-kDa granulysin is secreted by CTLs and NK cells and is present in blister fluid in SJS/TEN. This has a cytotoxic effect on keratinocytes and also acts as a

**Role of MHC**

The role of the MHC in drug allergy has received particular attention with regard to certain drugs and ethnic groups. The drug hypersensitivity syndrome caused by abacavir is strongly associated with HLA-B*5701 and key structures in the peptide binding cleft of HLA-B*5701 have been identified that permit non-covalent interactions with this drug. This binding may also occur in so-called empty, non-peptide bearing MHC class I molecules. The binding of abacavir to the F pocket of HLA-B*5701 alters the spectrum of self peptides that can be presented by this MHC class I molecule. This results in the display of a novel peptide repertoire that appears foreign to the immune system. Memory T cell responses in abacavir-hypersensitive donors are directed against a self-peptide that requires abacavir to efficiently bind to HLA-B*5701. The situation is then analogous to alloreactions with the development of a severe cytotoxic response through the activation of cross-reactive effector memory cytotoxic T cells. The rapidity of onset of the reaction and its intensity may depend upon differences in TCR avidity.

However, abacavir also appears to bind irreversibly to proteins in antigen-presenting cells, raising the possibility that in this case, both non-covalent and altered peptides mechanisms may be involved in the generation of the allergic drug reaction. The association with HLA-B*5701 is strong enough that the US Food and Drug Administration issued an alert in 2008 recommending pre-screening for this allele before prescribing the drug.

In Han Chinese and other Asian populations, Stevens-Johnson/Toxic Epidermal Necrolysis induced by carbamazepine is strongly associated with HLA-B*1502. This association does not exist in Europeans, where an association with HLA-A*3101 has been reported. It does not appear that carbamazepine covalently modifies peptides which are presented in MHC but rather that carbamazepine or it metabolites binds directly to endogenous peptides already present there. However, not all HLA-B*1502 bearing patients react in this way to carbamazepine. This appears to be due to the requirement for a particular structure of the T cell receptor. T cell clones from HLA-B*1502 donors with carbamazepine hypersensitivity express the predominant TCR clonotype VB-11-ISGSY. This was found in 84% of 19 patients with SJS/TEN but was absent in carbamazepine-tolerant patients. It is present in 14% of healthy subjects. If peripheral blood mononuclear cells from normal donors expressing HLA-B*1502 and VB-11-ISGSY were primed with carbamazepine, a cytotoxic T cell response was induced that could be blocked with anti-TCR-VB-11. Thus the appropriate HLA allele and T cell receptor clonotype is required for the carbamazepine immune response to occur in this population.

The severe mucocutaneous lesions of SJS/TEN are usually explained on the basis of cytotoxic T lymphocytes (CTLs) natural killer (NK) cell-mediated reactions. Three major types of reactions have been considered responsible for these reactions, 1) Fas-FasL (Fas Ligand) interactions, 2) the perforin/granzyme B pathway, 3) granulysin. Viard et al. proposed that Fas-FasL interactions were responsible for apoptosis of keratinocytes in SJS/TEN. However this hypothesis has been questioned and a role for perforin/granzyme B suggested. Activated CTLs and NK cells produce perforin and this can open a channel in the target cell membrane to allow granzyme B to enter, which activates the caspase cascade. The 15-kDa granulysin is secreted by CTLs and NK cells and is present in blister fluid in SJS/TEN. This has a cytotoxic effect on keratinocytes and also acts as a

**Figure 2. Activation of T cell &/or Dendritic cell by non-covalent binding of drug to T cell receptor or MHC**
chemoattractant for T cells, monocytes and other inflammatory cells.

**Role of Viruses**

Drugs are also frequently associated with viral infections and in most cases; the drug is blamed for the exanthema that occurs. Sometimes this is true and the patient has a persistent delayed-type allergy to aminopenicillins. But more often, the reaction does not recur on re-administration of the drug. The rash in this case may be caused by a lowering of the T cell threshold for drug reaction during the infection, or from infection-induced alterations in drug metabolism or virally-induced polyclonal T cell activation. Although Epstein-Barr virus infection is the best known example, other viruses similar predispose to drug-induced exanthema.

Drug-induced hypersensitivity syndrome (DIHS) is a multi-organ disorder characterized by cutaneous disease, eosinophilia and multi-organ failure occurring within 8 weeks after the introduction of a drug. The original description involved aromatic anticonvulsants and was termed “anticonvulsant hypersensitivity syndrome.” Later the name “drug rash with eosinophilia and systemic symptoms” (DRESS) was coined but this has been replaced by DIHS.

An intimate relationship appears to exist between viruses and the occurrence of DIHS.34 In this syndrome, it was demonstrated by PCR analysis that there occurs a multiple and sequential reactivation of Herpes viruses in DIHS. Investigations have shown, by lymphocyte transformation tests and patch tests, that drug-specific T cells are involved in initiating the syndrome.4 The drugs implicated in DIHS appear to be either chemically reactive, binding to antigen binding structures such as MHC or tissue proteins, or are metabolized to oxidative by-products that are reactive, or if chemically unreactive, like lamotrigine, bind non-covalently to the T cell receptor or MHC, as described in the p-I concept. The occurrence of T cell activation may reactivate viral genome in the T cells leading to an immune response against the virus. Takahashi et al.35 found an expansion of active T regulatory (Treg) cells during the acute phase of DIHS that might cause a sequential reactivation of Herpes viruses. As the condition begins to resolve, these cells lost their function, resulting in the potential for an increase in the risk of developing autoimmune disease.

Alternatively, the symptoms of DIHS may be due to both oligoclonal expansion of drug-specific T cells and virus-specific T cells that express cross-reactivity with drugs. Drug administration may expand these cross-reacting T cells, triggering latent virus reactivation. This might explain the association of relapses in the absence of the drug with virus reactivation, the involvement of multiple organs and the cross-reactivity with multiple drugs seen in DIHS. Of note, evidence of the viral genome is delayed 2–3 weeks from the start of the syndrome.36 One possible explanation for this is that several of the causative drugs have the potential to cause immune suppression. So viral clearance may only occur after drug withdrawal and symptoms may reflect the return of the immune response to the virus.

**Drug-Induced Liver Injury**

The liver is the site of metabolism for many drugs and reactive metabolites are formed frequently, yet reactions involving the immune system do not occur often. Perhaps it is necessary that drug metabolites be capable of generating danger signals such as high mobility group box (HMGB) 1, heat shock proteins and S100 proteins from damaged cells, to act as costimulators. It is also possible that damaged hepatocytes release damage-associated molecular pattern (DAMP) molecules which stimulate a proinflammatory response in innate immune cells such as neutrophils and macrophages.37 Such cells contain cytochrome 450 and/or peroxidase enzymes capable of generating reactive metabolites from drugs. Apoptotic and necrotic cells can also release DAMP molecules such as HMGB1 protein, heat shock proteins, hyaluran, surfactant protein, B-defensin and cardioliopin to act as stimulators of immune responses.

Halothane induced liver damage is characterized by initial mild liver injury, followed by, in a small percentage of patients, massive hepatocyte necrosis on re-exposure. An understanding of the mechanisms of this response is of importance, because of the reports of hepatitis with newer volatile anesthetics.38

A mouse model of halothane -induced liver injury has been described, particularly inducible in Balb/c mice.39-41 The model appears to be dependent upon formation of Trifluoroacetic acid-protein adducts but susceptibility is attributed to a differential activation of the innate immune system. After halothane exposure, there is an increase in proinflammatory cytokines such as TNF-a, IL-1B, IL-6 and iNOS. Evidence of an innate immune response was seen with increase of IL-8 and increased neutrophil infiltration into the liver. A role for neutrophils in the induction of liver damage was confirmed by neutrophil depleton studies. Using wild type and NKT cell-deficient CD1-/- mice, it was shown that these cells were involved in neutrophil recruitment into the liver. Other studies have suggested a role for NK cells and cytokines IL10 and IL-17. Therefore the innate inflammatory response may be an important determinant of drug-induced liver disease.

In some cases drug-induced liver disease involves the adaptive immune system. Flucloxacinilin causes cholestatic liver damage.40-42 The drug binds to lysine resides 190, 212 on human serum albumin and most T cell clones from flucloxacinill allergric patients are CD8+ Granzyme+. Flucloxacinilin stimulation of these T cells is HLA class I dependent and may be HLA-B*5701 restricted. Studies showed a three-fold increased risk of flucloxacinill hepatotoxicity in individuals with polymorphisms in the promoter region of the pregnane X receptor (PXR; also known as NR1I2), which is activated by flucloxacinill.

**Classification of Drug Reactions**

Allergic drug reactions are considered to be the result of drug recognition by the immune system with clinical manifestations that are not explainable by the known side effects of the drug. However frequently the pathophysiology of the reaction is unknown and it is considered to be allergic in nature because it
happens infrequently or to certain populations and the presentation is consistent with an immunological response.

Attempts are usually made to fit the manifestations of allergic drug reactions into the classification of Gell and Coombs. In this classification, Type 1 reactions are immediate, or IgE mediated, Type 2 reactions are caused by IgG or IgM antibodies directed to cell surface antigens, Type 3 reactions involve IgG antibodies against soluble antigens, forming immune complexes, and Type 4 reactions are cell-mediated, subdivided as a, b, c, and d.

Type 4a reactions are typified by the tuberculin skin reaction but may also participate in contact dermatitis and some bullous exanthema. They are considered to be Th1 reactions mediated by IFN-γ and TNF-α and monocyte and macrophages are the primary effectors. Type 4b reactions are exemplified as Th2 reactions, with IL-5, IL-4 and IL-13 and eotaxin driving eosinophilic inflammation. Examples include maculopapular and bullous exanthema. In Type 4c reactions, cytotoxic T cells are the primary mediators with perforin, granzyme B and FasL release causing contact dermatitis, maculopapular and bullous eruptions. Type 4d reactions involve T cells and CXCL8 and GM-CSF causing neutrophilic infiltrates leading to purpuric exanthema.

While there are individual examples of drugs that cause allergic reactions conforming to this classification, for many there is no definite proof that a particular mechanism is involved or multiple mechanisms can be implicated.

Immediate drug reactions or Gell and Coombs Type 1 reactions are the result of the cross-linking of drug-specific IgE molecules bound to mast cells and/or basophils. To do this, drugs must exist in a multivalent form expressing several epitopes and likely therefore bound to a peptide or protein molecule. If the drug is in its original state, expressing only a single epitope, cross-linking cannot occur. The exception would be drugs that can exist in a polymerized state in vivo such as succinylcholine and possibly aminopenicillins. When cross-linking occurs, mast cell degranulation results in the release of inflammatory mediators such as histamine; proteases (tryptase, chymase, carboxypeptidase); proteoglycans (heparin, chondroitin sulfate E); prostaglandins (PGD2); leukotrienes (LTC4); cytokines (TNF-α, IL-3, IL-4, IL-5, IL-6, IL-8, IL-16, GM-CSF); chemokines (CCL2, CCL3, CCL11). These factors cause the typical signs of anaphylaxis such as urticaria and angioedema as well as bronchospasm, hypotension and cardiac arrhythmias. While all drugs can potentially cause immediate reactions, β-lactam antibiotics are a common cause, as well as muscle relaxants.

For other low molecular weight drugs causing immediate reactions we know almost nothing about the epitopes involved unless they are demonstrable by skin or in vitro testing with the intact molecule.

Type 2 reactions are typified most commonly by hemolytic anemia, thrombocytopenia and neutropenia, in which drug or active drug metabolites bind to cell membranes and these epitopes become the target of drug-specific IgG or IgM antibodies, with subsequent complement activation and either hemolysis or phagocytosis in the reticulo-endothelial system. Again, penicillins are recognized to cause such reactions but so can cephalosporins, β-lactamase inhibitors and methyl-dopa.

Type 3 reactions are considered to be mediated by immune complexes, which requires the drug or its active metabolites to be covalently bound to a macromolecule such as albumin. An immune response to the drug-conjugate, usually in the form of IgG antibodies, then results in the formation of immune complexes that deposit in such organs as skin, kidney and joints. Since complement is activated, there is release of anaphylatoxins such as C3a and C5a, with induction of mast cell mediator release and attraction of neutrophils to the site of immune complex deposition. There may also be stimulation of an IgE response with subsequent mast cell activation. Such reactions are delayed for 8–10 days during the primary sensitization, but if the drug is readministered in a sensitized individual, the reaction is accelerated, occurring within 2 days of restarting the drug. Penicillins are again often associated with these reactions, as are cephalosporins and macrolides but commonest now as a cause are drug macromolecules such as monoclonal antibodies.

Many drugs are capable of inducing Type 4 reactions, which are believed to be the cause of most maculopapular eruptions. Some of these may be Type 4b and others Type 4c, a classification dependent on the histology of the rash or in vitro studies of the types of T cells involved and cytokines released. Most contact reactions to drugs appear to be either Type 4a or Type 4c.

Acute generalized exanthematous pustulosis is characterized by the development of acute, small, non-follicular sterile pustules beginning in the intertriginous folds with diffuse edema and erythema. There is fever and a peripheral leukocytosis. Histologically there occurs massive subcutaneous infiltration with neutrophils and T cell infiltration of the dermis and epidermis. When drug-induced, the lymphocyte transformation test shows marked reactivity to the causative drug. Drug-specific CD4 and CD8 positive T cells are found in the peripheral blood and these produce interleukin-8 (IL-8/CXCL8). The neutrophil infiltration may therefore be secondary to these cells infiltrating the skin, or drug-specific T cells may stimulate keratinocytes to produce IL-8. Another possibility is that IL-17-producing Th17 cells that co-express IL-22 are responsible for synergistically stimulating IL-8 production by keratinocytes.

Allergic responses to drugs that involve the adaptive immune system are dependent upon the activation of three different types of effector T cells, these being Th1, Th2 and Th17. While Th1 cells produce predominantly IFN-γ and generate a cell-mediated immune response, Th2 cells produce IL-4, IL-5 and IL-13 and stimulate IgE production, resulting in immediate Type 1 reactions, and Th17 cells are responsible for neutrophilic responses mediated through IL-17.

Differentiation of these Th cells is directed by antigen-presenting cells, most often dendritic cells. Dendritic cells can be activated by tissue damage and cell death, as well as by some drugs, which explains why allergic drug reactions frequently occur in association with viral, bacterial or other infections.

In the case of drug hapten-peptide conjugates, it remains uncertain what characteristics determine the type of Th cell activated. It is clear from clinical experience that penicillin is capable of inducing IgE, IgG and IgM responses, as well as cell-mediated responses, causing Type 1, Type 2, Type 3 or Type 4 reactions.
What factors determine which of these immune responses develops? In the case of Type 1 reactions, there is interesting data showing that basophils and mast cells can act as APC and induce Th2 responses. In circumstances where Type 2 reactions occur there has often been prolonged treatment with high dose β-lactam antibiotics. And in Type 3 reactions, there may be unique properties of the IgG antibodies specific for the drug hapten-protein conjugate that results in immune complex deposition in tissues, or there may occur concomitant generation of drug-specific IgE antibodies. For Type 4 reactions, in situations where T cell activation is via pharmacological interaction, responses will be T cell mediated, although this does not preclude Th cell activation and antibody production. In Type 4d reactions, Th17 cells may be involved, while Type 4c reactions may involve Th2 cells. Type 4b reactions involve cytotoxic T cells initially activated by Th1 helper cells.

Interesting studies by Pichler and his collaborators in Multiple Drug Hypersensitivity suggest a problem exists with persistent T cell activation in such patients, even in the absence of drug, perhaps implying in vivo activation by chronic viral infections such as Herpes virus, CMV, EBV etc. In such patients there does not seem to be a deficiency in Treg activity.

Drugs are often recognized as foreign by the immune system even in the absence of clinical hypersensitivity, so IgG and IgM antibodies to drugs may be found. So, what turns an innocuous immune response to a drug into clinical hypersensitivity? While a number of molecular characteristics of allergens have been described, such a < 70 kd size, low hydrophobicity, high stability, lack of bacterial protein sequences and the presence of allergen-specific patches with surface-exposed hydrophobic residues, none clearly define allergenicity and most would not apply to drug-modified self-proteins, although they could apply to drug-modified proteins from infectious agents. Development of drug allergy may indeed be because of other factors activating the innate immune system, such as viruses or bacteria, or the unique characteristics of the individual, including the presence of certain HLA alleles or T cell receptor structures that allow drug hypersensitivity to develop. However, the fact that individuals previously allergic to a drug can often tolerate the drug subsequently indicates that environmental influences are important.

Some drug reactions appear to conform to a Type 1 pattern with urticaria, angioedema and often bronchospasm, but actually do not involve the adaptive immune system at all. Examples of these would be reactions to narcotics, which stimulate direct histamine release from mast cells or basophils, certain antibiotics such as vancomycin, producing the “red man” syndrome by direct histamine release, and reactions to NSAIDS. The cause of the latter is still uncertain, with polymorphisms in cytochrome P4502C9, cyclo-oxygenase and lipoxygenase and thromboxane A2 receptor being associated with ASA-induced urticaria. Aspirin exacerbated respiratory disease (AERD) is a reaction similar to a Type I reaction but without production of IgE by the immune system, related to excessive production of leukotrienes by 5-lipoxygenase, which results in mast cell degranulation and release of mast cell mediators and cytokines, causing symptoms of rhinitis and asthma. Prostaglandin E2, produced via the cyclo-oxygenase pathway, is an inhibitor of 5-lipoxygenase. Aspirin inhibits production of PGE2, allowing increased leukotriene production. Reduced PGE2 synthesis also increases mast cell instability with enhanced release of histamine and other mediators. There is also evidence that IL-10 and TGF-b polymorphisms play a role in AERD. Angioedema is precipitated by Angiotensin converting enzyme inhibitors and although relatively rare, can be severe. Angiotensin converting enzyme catalyzes the conversion of Angiotensin I to Angiotensin II, but also degrades bradykinin, when the same enzyme is known as kininase II or dipeptidylkexopeptidase I. Inhibition of kininase II prevents degradation of bradykinin and other kinins, predisposing to development of angioedema. An association exists between low plasma levels of aminopeptidase P and angioedema because this enzyme is important in bradykinin metabolism when Angiotensin-converting Enzyme (ACE) is inhibited.

**Common Causes of Drug Reactions**

**Penicillins.** Penicillins are the most frequent cause of drug allergy, reportedly affecting about 10% of patients. However 90% of patients claiming to be allergic to penicillin will have negative skin tests for penicillin allergy. The commonest reactions associated with penicillins are anaphylaxis, urticaria and angioedema, or maculopapular rashes. Carbapenems do not exhibit a significant degree of cross reactivity with penicillin and may be administered in penicillin-allergic subjects after prophylactic skin tests with the relevant Carbapenem. Monobactams such as aztreonam are well tolerated in patients with penicillin allergy, but patients with an allergy to ceftazidime should avoid aztreonam. Second or third generation cephalosporins have a very low degree of cross-reactivity in penicillin allergic subjects. If penicillins are essential in a patient with proven penicillin allergy, then desensitization should be performed.

**Cephalosporins.** Cephalosporins most commonly cause maculopapular rashes and drug fever, with urticaria less commonly seen and anaphylaxis rare. Positive skin tests to penicillin are associated with a small increased risk of reacting to first generation cephalosporins. In those individuals with cephalosporin allergy, there is a very limited cross-reactivity between second and third generation cephalosporins and penicillins, particularly amino-penicillins, based on side chain similarities. In such patients, skin testing with the proposed antibiotic to be used is useful, or a graded challenge. In the presence of positive skin tests with the proposed drug, if there is no alternative, desensitization should be performed.

**Sulfonamides.** Sulfonamide antibiotics are often responsible for delayed maculo-papular rashes and drug fever, with urticaria less commonly seen and anaphylaxis rare. Positive skin tests to penicillin are associated with a small increased risk of reacting to first generation cephalosporins. In those individuals with cephalosporin allergy, there is a very limited cross-reactivity between second and third generation cephalosporins and penicillins, particularly amino-penicillins, based on side chain similarities. In such patients, skin testing with the proposed antibiotic to be used is useful, or a graded challenge. In the presence of positive skin tests with the proposed drug, if there is no alternative, desensitization should be performed.
response in those with TMP-SMX allergy and usually can be safely administered, except for sulfasalazine, which is degraded in the intestine to sulfapyridine, with an aromatic immunogenic determinant like sulfamethoxazole.62,63

Acetylsalicylic acid/NSAID reactions. Acetylsalicylic acid (ASA) and NSAIDS may be responsible for allergic reactions involving the adaptive immune system, but more frequently cause pseudo allergic reactions resulting from abnormalities of prostaglandin or leukotriene synthesis. Reactions include exacerbation of respiratory disease such as asthma or symptoms of nasal polyposis, urticaria, angioedema, and anaphylaxis. Almost all of these reactions are caused by cyclo-oxygenase 1 (cox-1) inhibitors. Such patients should carefully avoid cox-1 inhibitors unless they have been desensitized. Selective cox-2 inhibitors almost never cause such reactions and can be safely taken by patients with ASA/NSAID allergy.64

When urticaria/angioedema are caused by cox-1 inhibitors, it may be precipitated by all or some of that group of drugs. For example, ASA-sensitive patients may react to ibuprofen and naproxen but not to other cox-1 inhibitors. Patients with chronic urticaria often have exacerbations if they take a cox-1 inhibitor. However true allergic reactions to NSAIDS involving the adaptive immune response, such as those occurring to dicyclofenac are usually drug-specific and other cox-2 inhibitors are tolerated.65

Angioedema from ACE-inhibitors. Although angioedema from ACE-inhibitors is uncommon, developing in 0.1–2.2% of patients on ACE-inhibitors, it accounts for about one third of emergency room cases of angioedema. Such patients often end up being admitted to hospital and requiring intensive care management.69 Angioedema from ACE-inhibitor may occur soon after beginning therapy but can also occur after months or years of treatment. Risk factors, in addition to hereditary angioedema, include older age, female sex, smoking, NSAID use and ACE-inhibitor-induced cough. Concomitant treatment with statins and sirolimus is a risk factor. Because the angioedema is induced by kinins, it is not responsive to usual treatments such as epinephrine, anti-histamines and steroids. The new bradykinin receptor 2 antagonist Icatibant is likely to be effective.66

General anesthetics. Anaphylaxis occurs in patients undergoing general anesthesia. Investigation of such reaction is difficult because the patient is often exposed to multiple drugs and other agents administered over a short period of time. Reactions in such circumstances are often due to neuromuscular blocking agents, but have been reported with intravenous anesthetics such as propofol, thiopentone and etomidate, as well as antibiotics, NSAIDS and latex. Inhaled anesthetics are not found to be responsible. Chlorhexidine and ethylene oxide have been recently incriminated in intra-operative anaphylaxis.67

Allergic reactions to biological agents. Chimeric monoclonal antibodies such as infliximab, because they contain variable regions that are murine in origin, can stimulate an immune response. The presence of such antibodies varies from 12–60%, dependent upon the population studied. Humanized monoclonal antibodies such as alemtuzumab can induce immune responses in as many as 23% of patients with multiple sclerosis and fully human antibodies such as adalumumab are immunogenic in 3–4% of patients with Crohn’s disease and even higher levels are seen in Rheumatoid arthritis patients. Recombinant biologics such as abatacept and etanercept elicit antibody responses in up to 18% and 3% of patients respectively. The frequency of antibody production to biologics clearly varies with the populations studied. For example, rituximab induces antibodies in 1% of patients with B cell malignancies, 25% of patients with Sjogren’s syndrome and 40% of patients with SLE.68

Most anti-drug antibodies are IgG in isotype but a proportion of reactions have been associated with IgE antibodies. These have been found to occur with infliximab, tocilizumab, cetuximab, natalizumab and muromonab, as well as rituximab and trastuzumab.

A number of infusion reactions occurring with monoclonals are the result of massive cytokine release by cells such as macrocytes, macrophages, T cells, B cells and NK cells. This is an acute phase reaction indistinguishable from an IgE mediated reaction but occurring as a result of the first administration.

Stevens-Johnson and toxic epidermal necrolysis. The commonest drug causes of SJS and TEN are sulfonamides, allopurinol, carbamazepine, phenytoin and NSAIDS of the oxicam type. New drugs with increased risk are nevirapine and lamotrigine.27,31,69

Although a strong association in Han Chinese has been shown for HLA-B*1501 and SJS, this has only been duplicated in a Thai population and in Europe, this allele is not a marker for SJS caused by carbamazepine, sulfonamides, lamotrigine or oxicam-NSAIDS. In Han Chinese HLA-B*1501 is associated with phenytoin and lamotrigine- induced severe cutaneous reactions.

A second association has been reported for allopurinol in the case of HLA-B*5801 in Han Chinese, Thai patients and Europeans.

Drug-induced hypersensitivity syndrome. This syndrome is characterized by an extensive mucocutaneous rash, fever, lymphadenopathy, hepatitis, eosinophilia and atypical lymphocytosis with damage to kidneys, heart, lungs and pancreas.21 It occurs 3 weeks to 3 mo after beginning drug therapy and may persist or worsen after withdrawal of the medication. It is rare but more common than SJS. It is seen most commonly with anticonvulsants, antidepressants, sulfonamides and sulfones, NAIDS, anti-infective agents, Angiotensin converting enzyme inhibitors and betablockers. The most typical forms of DIHS occur with aromatic anticonvulsants, dapsone, sulfapyridine, allopurinol and minocycline. As noted previously, studies suggest a close relationship between DIHS and reactivation of Herpes 6 virus.

Drug-induced liver injury. Drug-induced Liver Injury (DILI) can be caused by drugs such as halothane, tienilic acid, hydralazine, dicyclofenac and carbamazepine where the reaction occurs within 1–8 weeks, is associated with rash, fever, eosinophilia and recurs rapidly on re-challenge.70 There may also be present specific antibodies against hepatic proteins either native or drug-modified. There is also increasing evidence of an association between DILI and certain MHC class I and II alleles where the drugs involved are amoxicillin-clavulinate, fluoxacillin, ticlopidine, ximelagatran, lumiracoxib and lapatinib.
Drug desensitization is indicated when (1) no alternative drug is available, (2) the drug is more effective than alternatives, (3) there are no co-morbid factors placing the patient at increased risk, (4) the previous reaction to the drug was not a severe, life-threatening immediate reaction to drugs in humans. By incremental administration of increasing amounts of drug, hypo-responsiveness of these cells is induced without anaphylaxis occurring. The tolerization in the individual patient is temporary.\(^75\)

The desensitization process may (1) deplete the cells of activating signal transduction components such as syk kinase, (2) depletion of mediators, (3) internalization of FcεRI through progressive cross-linking at low antigen concentration. There is evidence that the desensitized state persists as long as antigen is present in the environment but mediator release can occur again when antigen is removed. Signaling pathways thus remain intact for a second stimulus. In addition, FcεRI is not depleted from the mast cell surface. A fourth possibility that may apply in certain circumstances that would explain the ability to induced degranulation with a second allergen is haptenation of the specific IgE on the cell surface, such that cross-linking cannot occur. In human basophils downregulation of FcεRI occurs during IgE activation but takes many hours to days. Three mechanisms may play a role in the termination of secretory signals in basophils. These are activation of SHIP, processing of syk by ubiquination and the degradation and loss of FcεRI receptors. A fourth mechanism, undefined as yet, involves resorting of receptors in the cell membrane. Two of these mechanisms appear to

### Table 1. Common drug allergies and desensitizations

| Drugs               | Common allergic reactions | Standardized desensitization | References |
|---------------------|--------------------------|------------------------------|------------|
| Penicillins         | Anaphylaxis, urticaria, angioedema | Yes | 72, 95 |
| Other β-lactams     | Urticaria, angioedema, Anaphylaxis | Yes | 75 |
| Platins             | Anaphylaxis, anaphylactoid | Yes | 75 |
| Monoclonals         | Anaphylaxis | Yes | 96 |
| Taxanes             | Anaphylaxis, anaphylactoid | Yes | 46 |
| Muscle relaxants    | Anaphylaxis | No |
| ASA                 | Asthma, urticaria, angioedema | Yes | 57, 80 |
| Angiotensin-inhibitors | Angioedema | No |
| Sulphamethoxazole   | Maculopapular rashes | Yes | 94, 97 |
| Anti-convulsants    | Drug-induced hypersensitivity | No |
| Multiple drugs, e.g. sulphonamides, abacavir | Stevens-Johnson, Toxic epidermal necrolysis | No |
| Multiple drugs, e.g., flucloxacillin | Drug-induced liver disease | No |

**Desensitization in Immediate Allergy**

However anecdotal reports of desensitization for many types of drug allergy are reported, usually involving very limited numbers of patients. A website-based database of drug allergy case reports and desensitization protocols would therefore be of value.

**Animal models.** Woo et al.\(^73\) developed a murine model of systemic anaphylaxis to penicillin V. These allergic mice were desensitized by oral feeding with the drug, by five feedings of doubling doses every 15 min. Desensitization was determined by testing for the induction of active systemic and active cutaneous anaphylaxis and by measurement of plasma levels of platelet-activating factor and histamine. Mice fed more than 3 mg of a cumulative dose of penicillin V were completely protected from fatal systemic anaphylaxis but the desensitized state lasted only for about one hour. Antigen-specific mast cell desensitization appeared to be the mechanism for the desensitized state and not hapten inhibition, consumption of IgE or depletion of mast cell mediators. The authors suggested that the desensitization might result from the internalization of penicillin-specific IgE antibodies and that subsequent recycling of the internalized antibodies could lead to a recurrence of anaphylactic sensitivity.

Park et al.\(^74\) investigated the effect of anti-IL-4 antibody in a murine model of penicillin V and cephalothin anaphylaxis. The IgE mediated state resulted in fatal reactions in 100% and 70–90% of animals with penicillin V and cephalothin administration. Administration of anti-IL-4 at the beginning of the sensitization procedure completely prevented anaphylaxis. But anti-IL-4 was also effective for 21 days in preventing fatal anaphylaxis when given to previously sensitized mice. This was associated with a fall in specific IgE levels in the treated animals. This has not been tested in humans.

**Effects on mast cell and basophils.** It is thought that mast cells and perhaps basophils are the targets for desensitization in immediate reactions to drugs in humans. By incremental administration of increasing amounts of drug, hypo-responsiveness of these cells is induced without anaphylaxis occurring. The tolerization in the individual patient is temporary.\(^75\)

The desensitization process may (1) deplete the cells of activating signal transduction components such as syk kinase, (2) depletion of mediators, (3) internalization of FcεRI through progressive cross-linking at low antigen concentration. There is evidence that the desensitized state persists as long as antigen is present in the environment but mediator release can occur again when antigen is removed. Signaling pathways thus remain intact for a second stimulus. In addition, FcεRI is not depleted from the mast cell surface. A fourth possibility that may apply in certain circumstances that would explain the ability to induced degranulation with a second allergen is haptenation of the specific IgE on the cell surface, such that cross-linking cannot occur. In human basophils downregulation of FcεRI occurs during IgE activation but takes many hours to days. Three mechanisms may play a role in the termination of secretory signals in basophils. These are activation of SHIP, processing of syk by ubiquination and the degradation and loss of FcεRI receptors. A fourth mechanism, undefined as yet, involves resorting of receptors in the cell membrane. Two of these mechanisms appear to
be the result of weak signaling. Downregulation of syk occurs with concentrations of allergen that do not induce secretion. Loss or downregulation of FceR1 can be demonstrated but does not occur with subthreshold stimulation.75

The studies of MacGlashan76 demonstrated that subthreshold desensitization of human basophils results in loss of syk and loss of cell surface receptor. These changes occur progressively over an extended period of time, without significant histamine release. It is assumed that during subthreshold stimulation, even though histamine release is not occurring, there is still present some signaling that mediates desensitization. Receptor loss appears not to be sensitive to the activities of syk, but is sensitive to the activities of src-family kinases. So loss of syk and loss of receptor expression may be disconnected under appropriate conditions.

Of considerable interest is the finding that when BPO2 and BPO(12)-HSA are compared in their ability to induce syk loss in basophils sensitized with BPO-specific IgE, there was only a small difference in the loss of syk for similar loading of the cell, even though histamine release was considerably different. It therefore seems that aggregate size is not a strong determinant of syk loss.

Benzylpeniciloilformyl-lysine or Ro-6-0787, a single epitope of the major antigenic determinant of benzylpenicillin, was used by De Weck and his collaborators to desensitize patients with penicillin allergy by haptenation of IgE in a multicenter study of 90 patients.77 Ro-6-0787 alone was successful in 17 of 26 patients, and combined with penicillin therapy, was successful in 42 of 46 cases. There was after its' administration a depression of skin test reactivity to PPL and/or penicillin derivatives. But its use was unsuccessful in 11 cases and 5% of penicillin allergic subjects showed positive skin test reactions to this monovalent hapten. This study would appear to show that in some cases of penicillin allergy, that hapten inhibition of IgE is a potential cause of desensitization, but such a strategy would not be effective in those patients who were allergic to minor determinants.

**Desensitization in NSAID sensitivity.** Stevenson et al.78 reported in 1980 that two patients, who became refractory to ASA after oral challenge, noticed subsequent improvement in nasal obstruction and ability to smell. A randomized double blind placebo-controlled crossover trial of ASA desensitization in 25 patients with ASA-sensitive asthma subsequent showed significant improvement in symptoms of rhinosinusitis and decrease in daily nasal corticosteroid use while on ASA, but no effect on asthma was noted.79 A retrospective review of 107 patients with ASA sensitivity with rhinosinusitis compared 65 patients who were desensitized to ASA compared with 42 patients who simply avoided all NSAIDS.80 There were significant reductions in number of hospitalizations, ER visits, outpatient visits, sinusitis and sinus operations in the intervention group. There was also a reduced need for systemic steroids.81 Subsequent longer term studies have shown benefit of ASA desensitization in terms of sinus symptoms, medication use and need for endoscopic sinus surgery, with operations reduced from every 3 years on average to every 9 years.82

While the above studies describe the effects of oral desensitization with ASA, other methods have included local desensitization using l-lysine aspirin. This has been carried both intranasally and by bronchial inhalation.83,84

In patients with ASA-induced asthma and rhinosinusitis, after ASA-lysin desensitization, the number of inflammatory cells in the nasal tissues expressing Cys-LT1 receptors became normal after 5 mo of therapy. Production of thromboxane B2 by monocytes was reduced and LTB4 synthesis normalized after chronic ASA therapy following desensitization. LTE4 levels in urine were reduced, but not to normal levels.

ASA has been shown to inhibit activation of transcription factor-kB to inhibit IL-4 and IL-13 activation of STAT-6.85 So after desensitization, ASA may inhibit the inflammatory response as well as affecting prostaglandin and leukotriene production. But the precise mechanism by which ASA desensitization produces benefit remains unknown.

**Desensitization in Cell-mediated Reactions**

**Animal models.** Phenytoin is a widely used anticonvulsant for treatment of focal and generalized tonic clonic seizures. It induces maculopapular rashes as well as SJS, TEN, exfoliative dermatitis and fixed drug eruptions. It is also responsible for DIHS with fever, rash and lymphadenopathy. In such delayed reactions, identification of allergen-specific T cells may be important. This may be achieved by patch testing or delayed skin testing, or by lymphocyte transformation testing, but these methods lack sensitivity and false negative tests are common. Recently, Turcanu et al.86 described a carboxyfluorescein succinimidyl ester (CFSE) for identification of food allergen-specific T cells. This approach has been applied to patients with reactions to phenytoin to examine frequency and cytokine-producing phenotypes of CD4+ and CD4- T cells.

Phenytoin-specific proliferation and cytokine production was shown by the CFSE dilution assay with a sensitivity of 100% for proliferation in the CFSE assay and 71.4% for IFN-γ production.87 Both CD4+ and CD4- cells responded with production of IFN-γ and TNF-α.

In a patient with phenytoin allergy, manifest by maculopapular rash appearing after 12 days therapy, which was treated with clinical desensitization, an effect of desensitization was shown on phenytoin responsive CD4+ and CD4- T cells.88 Before desensitization, these numbered 3.09% and 3.18% respectively, by CFSE assay, with IFN-γ-positive cells 13.6% and 12.3% respectively. But after desensitization, no IFN-γ producing cells were demonstrable and phenytoin responsive cells in the CFSE assay were 0.16% and 1.26% in the CD4+ and CD4- T cell populations. The mechanism for this desensitization process and how these drug-specific T cells are tolerized or inhibited is unclear.

A possible explanation might be through the activation of T regulatory cells.89,90 Although there is no direct evidence for this, it is of interest that fixed drug reactions, where drug-specific CD4+ and CD8+ T cells have been demonstrated, the amelioration of the skin lesions coincides with an influx into the skin of Foxp3+ regulatory T cells. Teraki and Shiohara91 showed in a patient with allopurinol fixed drug reaction that desensitization was associated with an influx of CD4+ CD25+ T cells into the

www.landesbioscience.com Human Vaccines & Immunotherapeutics 1521
Desensitization in presumed delayed cell-mediated reactions in patients has been performed in individuals who have developed morbilliform reactions to drugs such as sulfamethoxazole and allopurinol as well as in fixed drug reactions.92,93 These protocols follow the general principles of rapid desensitization but are performed over a longer period, varying from two days to eight days. In the case of sulfamethoxazole, the desensitization is successful more than 80% of the time, depending upon patient selection. Demoly et al.94 have recently described a six hour graded challenge that was successful in 95% of patients. However the mechanism involved in the desensitization, which presumably involves induction of some form of T cell tolerance or anergy, remains unknown.

Desensitization Allergy to Chemotherapeutic Agents

Castells and associates have developed protocols for desensitization with chemotherapeutic agents in patients who have suffered a Type 1 immediate hypersensitivity reaction, whether IgE or non-IgE mediated.46,47 The protocol is 12 to 20 steps based, with doubling doses starting at 1/1,000 of the final dose. This protocol, which has been used for paclitaxel and doctaxel, cisplatin, carboplatin, oxaliplatin and monoclonals such as rituximab, infliximab, trastuzumab, omalizumab, natalizumab, basiliximab, abiximab and cetuximab, is preceded by routine premedication with diphenhydramine and famotidine, which may be supplemented with aspirin, montelukast or glucocorticoids. Beta-adrenergic antagonists are discontinued for 24 hours. Desensitization with taxanes is generally well tolerated, with a series of 98 patients undergoing 413 desensitizations with only mild or no reactions. The success of rapid desensitization with platins appears to be similar. For monoclonal antibody desensitization, reaction rates are approximately 30% with 90% of these being mild. In the small percentage of cases with severe reactions, these occurred in patients with positive skin tests to the agent that was administered.

Summary

While we have learned a great deal about the pathogenesis of allergic drug reactions in terms of immediate allergy to penicillins and the role of MHC and viruses in some serious forms of drug allergy, such as SJS/TEN and DIHS, we know much less about the immunological processes involved in common drug reactions such as maculo- papular eruptions. Therefore our diagnostic techniques for demonstrating the presence of delayed drug allergy are severely limited and we lack an understanding of the mechanisms of desensitization in such situations. In the future, animal models may help to clarify these issues but, as is seen in SJS/TEN and DIHS, there are very specific requirements that must be met for drug allergy to occur which it may not be possible to model. More probable is that the development of sophisticated immunological techniques will allow careful dissection of the drug-immune response in human. Of great importance is the ability to develop predictive models that will allow the identification of patients at high risk of adverse reactions to drugs. We should not be surprised by the complexity of this problem, given system did not evolve to deal with multiple man-made chemicals, that the human immune.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ 1998; 316:1295-8; PMID:9554092; http://dx.doi.org/10.1136/ bmj.316.7140.1295.
2. Pichler WJ, Naishirt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol 2011; 127(Suppl):S74-81; PMID:21354503; http://dx.doi.org/10.1016/j.jaci.2010.11.048.
3. McKinnon RP, Wildsmith JA. Histaminoid reactions in anaesthesia. Br J Anaesth 1995; 74:217-28; PMID:7555078; http://dx.doi.org/10.1093/bja/74.2.217.
4. Idoe O, Gutfre T, Willcoxon RR, de Weck AL. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 1968; 38:159-88; PMID:5352996.
5. Meng X, Jenkins RE, Berry NG, Maggs JL, Farrell J, Lane CS, et al. Direct evidence for the formation of diastereoisomeric benzylpenicilloyl haptens from benzylpenicillin and benzylpenicillic acid in patients. J Pharmacol Exp Ther 2011; 338:841-9; PMID:2168886; http://dx.doi.org/10.1124/jpet.111.183871.
6. El-Ghaiesh S, Monshi MM, Whitaker P, Jenkins R, Meng X, Farrell J, et al. Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis. J Pharmacol Exp Ther 2012; 341:597-610; PMID:22371438; http://dx.doi.org/10.1124/jpet.111.190900.
7. Levine BB. Immunologic mechanisms of penicillin allergy. A haptenic model system for the study of allergic diseases of man. N Engl J Med 1966; 275:1115-25; PMID:5923027; http://dx.doi.org/10.1056/NEJM1966112725009.
8. Pichler WJ. Immune mechanism of drug hypersensitivity; Immunol Allergy Clin North Am 2004; 24:737-97, v-vii; PMID:15247717; http://dx.doi.org/10.1016/j. jaci.2004.03.012.
9. Perez-Inestrosa E, Suau R, Montañez MI, Rodriguez R, Mayorga C, Torres MJ, et al. Cephalosporin chemiluminescence and its immunological implications. Curr Opin Allergy Clin Immunol 2005; 5:323-30; PMID:15958514; http://dx.doi.org/10.1097/01. jiac.0000173788.73401.69.
10. Elsheikh A, Castejón L, Lavergne SN, Whitaker P, Monshi M, Callan HE, et al. Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. J Allergy Clin Immunol 2011; 127:1543-51, e3; PMID:21354601; http://dx.doi.org/10.1016/j.jaci.2010.12.1119.
11. Wang D, Para MF, Kolelar SL, Sade W. Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenet Genomics 2011; 21:652-6; PMID:21878835; http://dx.doi.org/10.1097/ FPC.0b013e328349ee9.
12. Zabert-ul-Haq, Khan W. Molecular and structural determinants of adamantyl susceptibility to HLA-DRB allelic variants: an in silico approach to understand the mechanism of MLEs. J Comput Aided Mol Des 2011; 25:81-101; PMID:21116684; http://dx.doi. org/10.1007/s10822-010-9404-4.
13. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2:301-5; PMID:12139944; http://dx.doi.org/10.1097/01.jop.2002.020800-0003.
14. IUPAC recommendation on nomenclature and symbols. Clinical Chemistry Division Commision on Toxicology. Glossary of terms used in toxicology synopsis. Acta Pol Pharm 1992; 49:1-3; PMID:16092424.
15. Ureche J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47:513-39; PMID:16879083; http://dx.doi.org/10.1146/ annurev.pharm.47.120505.105150.
16. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy 2007; 37:998-99; PMID:17581192; http://dx.doi.org/10.1111/j.1365-2222.2007.02742.x.
17. Lavergne SN, Wang H, Callan HE, Park BK, Naishirt DJ. “Danger” conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells. J Pharmacol Exp Ther 2009; 331:372-81; PMID:19666748; http://dx.doi.org/10.1124/j pet.109.155374.
Chung WH, Wei P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-3; PMID:9774429; http://dx.doi.org/10.1126/sci ence.282.5388.490.

Hansafu T, Azukizawa H, Matsumura S, Katayama I. The predominant drug-specific T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant-induced hypersensitivity: mechanisms of a new concept. Annu Rev Pharmacol Tox iciol 2012; 52:401-31; PMID:22017685; http://dx.doi.org/10.1146/annurev-pharmaco logy-012811-154301.

Kano Y, Shiohara T. The variable clinical picture with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am 2010; 29:481-501; PMID:19563993; http://dx.doi.org/10.1016/j.iac.2009.04.007.

Chessman D, Kostenko L, Lethborg T, Purcell AW, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486:554-8; PMID:22722860.

Muh HC, Tong JC, Tammi MT. AllerHunter: a SVM-pairwise system for assessment of allergenicity and allergic cross-reactivity in proteins. Proteomics 2009; 9:4586-91; PMID:19516000; http://dx.doi.org/10.1007/s12016-008-9526-2.

Vasekar M, Craig TJ. ACE inhibitor-induced angioedema. Curr Allergy Asthma Rep 2011; 11:558-66; PMID:21952966; http://dx.doi.org/10.1007/ja.c2012.08.003.

Sjogren E, Hammarstrom C, Sandstrom T, et al. Almost all HLA variants associated with chronic spontaneous urticaria are encoded by a single chromosome. J Allergy Clin Immunol 2012; 129:884-901; PMID:22576054; http://dx.doi.org/10.1016/j.jaci.2012.04.002.

Sanderson JP, Naisbitt DJ, Farrell J, Tu cker J, et al. HLA-genotyped DNA archive from healthy volunteers. J Allergy Clin Immunol 2012; PMID:22576054; http://dx.doi.org/10.1016/j.jaci.2012.04.002.

Bharadwaj M, Illing P, Theodossis A, Purcell AW, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486:554-8; PMID:22722860.
75. del Carmen Sancho M, Breslow R, Sloane D, Woo HY, Kim YS, Kang NI, Chung WC, Song CH, Neuman MG, Cohen L, Nanau RM, Hwang PA.

68. Liu A, Fanning L, Chong H, Fernandez J, Sloane D, Chaudhry T, Hissaria P, Wiese M, Heddle R, Kette Zawodniak A, Lochmatter P, Beeler A, Pichler WJ.

65. Chaudhry T, Hissaria P, Wiese M, Heddle R, Kette Zawodniak A, Lochmatter P, Beeler A, Pichler WJ.

63. Zawodniak A, Lochmatter P, Rieder A, Pichler WJ.

62. de Hoog R, Simon RA, Mathison DA. Aspirin desensitization and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001; 44:231-8; PMID:11221250; http://dx.doi.org/10.1002/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7.

61. Lin D, Li WK, Rieder MJ. Corticosteroids for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to corticosteroids. Cochrane Database Syst Rev 2007; CD005646; PMID:17443608.

Fam AG, Dunne SM, Lazzara J, Paron TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 1999; 40:1789-92; PMID:9959344; http://dx.doi.org/10.1002/art.12222.

59. Stevenson DD, Pleskow WW, Simon RA, Mathison DA, Lumry WR, Scharz M, et al. Aspirin-sensitive rhinosinusitis: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984; 73:500-7; PMID:666649; http://dx.doi.org/10.1016/0091-6749(84)90361-0.

58. Stevenson DD, Hammad MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis: long-term outcomes. J Allergy Clin Immunol 2003; 111:180-6; PMID:12523216; http://dx.doi.org/10.1016/S0091-6749(03)00438-5.

57. Stevenson DD, Hammad MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis: long-term outcomes. J Allergy Clin Immunol 2003; 111:180-6; PMID:12523216; http://dx.doi.org/10.1016/S0091-6749(03)00438-5.

56. Stevenson DD, Pleskow WW, Simon RA, Mathison DA, Lumry WR, Scharz M, et al. Aspirin-sensitive rhinosinusitis: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984; 73:500-7; PMID:666649; http://dx.doi.org/10.1016/0091-6749(84)90361-0.

55. Stevenson DD, Pleskow WW, Simon RA, Mathison DA, Lumry WR, Scharz M, et al. Aspirin-sensitive rhinosinusitis: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984; 73:500-7; PMID:666649; http://dx.doi.org/10.1016/0091-6749(84)90361-0.

54. Stevenson DD, Pleskow WW, Simon RA, Mathison DA, Lumry WR, Scharz M, et al. Aspirin-sensitive rhinosinusitis: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984; 73:500-7; PMID:666649; http://dx.doi.org/10.1016/0091-6749(84)90361-0.

53. Stevenson DD, Hammad MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis: long-term outcomes. J Allergy Clin Immunol 2003; 111:180-6; PMID:12523216; http://dx.doi.org/10.1016/S0091-6749(03)00438-5.

52. Stevenson DD, Hammad MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis: long-term outcomes. J Allergy Clin Immunol 2003; 111:180-6; PMID:12523216; http://dx.doi.org/10.1016/S0091-6749(03)00438-5.

51. Stevenson DD, Hammad MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis: long-term outcomes. J Allergy Clin Immunol 2003; 111:180-6; PMID:12523216; http://dx.doi.org/10.1016/S0091-6749(03)00438-5.

50. Stevenson DD, Hammad MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis: long-term outcomes. J Allergy Clin Immunol 2003; 111:180-6; PMID:12523216; http://dx.doi.org/10.1016/S0091-6749(03)00438-5.

49. Stevenson DD, Hammad MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis: long-term outcomes. J Allergy Clin Immunol 2003; 111:180-6; PMID:12523216; http://dx.doi.org/10.1016/S0091-6749(03)00438-5.

48. Stevenson DD, Hammad MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis: long-term outcomes. J Allergy Clin Immunol 2003; 111:180-6; PMID:12523216; http://dx.doi.org/10.1016/S0091-6749(03)00438-5.

47. Stevenson DD, Hammad MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis: long-term outcomes. J Allergy Clin Immunol 2003; 111:180-6; PMID:12523216; http://dx.doi.org/10.1016/S0091-6749(03)00438-5.

46. Stevenson DD, Hammad MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis: long-term outcomes. J Allergy Clin Immunol 2003; 111:180-6; PMID:12523216; http://dx.doi.org/10.1016/S0091-6749(03)00438-5.